Literature DB >> 20368636

Reply to Drs. Olanow and Rascol.

J Eric Ahlskog1, Ryan J Uitti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368636      PMCID: PMC2865778          DOI: 10.1212/WNL.0b013e3181d7d93b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  3 in total

1.  A responsive outcome for Parkinson's disease neuroprotection futility studies.

Authors:  Jordan J Elm; Christopher G Goetz; Bernard Ravina; Kathleen Shannon; George Fredrick Wooten; Caroline M Tanner; Yuko Y Palesch; Peng Huang; Paulo Guimaraes; Cornelia Kamp; Barbara C Tilley; Karl Kieburtz
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

2.  Effect of deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

3.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1993-01-21       Impact factor: 91.245

  3 in total
  3 in total

Review 1.  Time to change the blind men and the elephant approach to Parkinson disease?

Authors:  Brad A Racette; Allison W Willis
Journal:  Neurology       Date:  2015-06-12       Impact factor: 9.910

Review 2.  Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

3.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.